anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide an effective method for treating a female suffering from female sexual dysfunction (FSD), in particular, female sexual arousal dysfunction (FSAD).  <P>SOLUTION: A method for assaying an agent capable of potentiating cAMP in the sexual genitalia of the female suffering from female sexual dysfunction, in particular, female sexual arousal dysfunction is provided. The agent is an inhibitor of neuropeptide Y (I:NPY). A method and a kit for detecting female sexual dysfunction, in particular, female sexual arousal dysfunction are provided. Non-human animal models, including an anesthetized female animal having a means for measuring change of genitalial blood flow of the animal accompanied with pelvic nerve stimulation, for identifying the agent for treating female sexual dysfunction, in particular, female sexual arousal dysfunction are provided.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Anaplasia in Wilms tumor is recognized as the most important prognostically unfavorable histological feature. It is subtyped as focal anaplastic Wilms tumor (FAWT) and diffuse anaplastic Wilms tumor (DAWT). Outcomes of patients with DAWT remain poor in patients with stage III and IV tumors. Important issues relevant to anaplasia in Wilms tumor, including prevalence, treatment, outcomes, biomarkers, anaplasia, and chemotherapy, and the concept of tumor aggressiveness, are reviewed and discussed here. We also consider the differences in clinical approaches to anaplasia in Wilms tumor between the two major renal tumor clinical research groups: the International Society of Paediatric Oncology (SIOP) Renal Tumour Study Group and the Children's Oncology Group (COG) Renal Tumor Group. We emphasize the importance and implications of recognizing FAWT and DAWT as separate clinico-pathological entities.
PCT No. PCT/KR98/00017 Sec. 371 Date Sep. 29, 1998 Sec. 102(e) Date Sep. 29, 1998 PCT Filed Jan. 24, 1998 PCT Pub. No. WO98/32434 PCT Pub. Date Jul. 30, 1998The present invention is related to a new analgesic composition of acetaminophen targeting decreasing of liver toxicity and releasing of hangover, which comprises aspartic acid promoting alcohol metabolism and methionine alleviating liver toxicity of acetaminophen. The analgesic combination preparation according to the present invention showed same analgesic and excellent protection effect against liver toxicity compared with the single preparation of acetaminophen, and decreased the blood concentration of alcohol and acetaldehyde causing hangover through improving metabolism rates of them. The combination preparation according to the present invention, therefore, is coincident with ideal new analgesic composition of acetaminophen having a minimized side effect and a hangover releasing effect.
The invention discloses a hair-growing solution which is prepared from following raw materials comprising, by weight, 30-50g of raw ficus microcarpa aerial roots, 10-30g of raw inflorescence of spatholirion longifolium, 6-10g of cynanchum paniculatum, 10-20g of raw kusnezoff monkshood roots, 10-30g of artemisia rupetris, 3-10g of tripterygium glycosides with peels, and 3-10g of raw semen strychni. In the hair-growing solution, the raw materials are weighed according to a weight ratio. The seven medicines, the raw ficus microcarpa aerial roots, the raw inflorescence of the spatholirion longifolium, the cynanchum paniculatum, the raw kusnezoff monkshood roots, the artemisia rupetris, the tripterygium glycosides with the peels and the raw semen strychni, are all preferably selected from fresh raw Chinese herbal medicines; if the fresh medicines cannot be obtained, dried fresh medicines are also available but must be obtained in a natural air-drying manner and must not be subjected to other processing methods. The tripterygium glycosides must be employed with peels. The raw materials are soaked in 1000 ml of a 75% alcohol solution for one week, and are stored away from light and in a sealing manner for later use. The hair-growing solution is easy to prepare, is low in cost and is effective. All the medicines are fresh nature national herbal drugs and are abundant in sources. The hair-growing solution is used as a painting liquid in an externally-use, is safe without side effects. The hair-growing solution, in clinical use, is used locally on an alopecia position with combination of knocking and stabbing by a needle onto skin so that the hair-growing solution can fully penetrate into subcutaneous hair follicle, can stimulate nerves of scalp and can promote growth of hairs.
An interplay between left atrial (LA) ganglionated plexi (GP), a part of the intrinsic cardiac autonomic nervous system (CANS), and pulmonary veins (PVs) is considered to be an important mechanism related with the initiation and maintenance of atrial fibrillation (AF). Therefore additional GP ablation has been reported with better ablation outcomes when added to RF-based PV isolation (PVI). A cryoballoon ablation (CBA) is an anatomically based approach which allows PVI that is highly safe and efficacious. The extension of the scar created by the cryoballoon frequently extends beyond the PV orifice in the acute and chronic post-ablation phase creating a set of lesions that are near the LA-GP area and inadvertent damage. A marked vagal response (VR) observed during CBA is considered a marker for the CANS modification. However, changes in the autonomic tone were independently noted from the presence of VR in several studies. Moreover, it is not clear if these changes are transient or long-lasting, and it has been shown that the presence of VR increases ablation success although with conflicting results. In previous studies assessing the influence of CBA on the autonomic balance, CANS modulation was appraised with different surrogates, a small number of individuals were usually recruited and both paroxysmal and persistent AF populations were included. Therefore, the investigators sought to evaluate the incidence of VR observed during CBA-based PVI, its impact on CANS assessed with widely accepted heart rate variability (HRV) analysis, and in relation to ablation outcomes in a large paroxysmal AF (PAF) cohort.
Following an overnight fast for at least 10 hours, participants will receive PF-04965842 oral single dose of 200 mg (2 × 100 mg tablets) on Day 1, at approximately 08:00 am plus or minus 2 hours in the morning. On Days 3 to 8, participants will receive PF-04965842 oral dose of 200 mg (2 × 100 mg tablets) QD in the morning at approximately similar clock hour as on Day 1. On Day 3 and Day 6-8, the dosing of PF-04965842 will be after collection of pre-dose blood samples (under fasted condition for at least 10 hours). On Day 8, the dosing will be under fasted condition at approximately 8:00 am plus or minus 2 hours in the morning.
Remedies for pain which contain as the active ingredient compounds having bo th of an opioid .mu. receptor agonist activity and a dopamine D2 receptor antagonist activity. The compounds having both of these activities exert a potent morphine-like analgetic effect but cause no mental dependency. Moreover, these compounds can regulate side effects. In particular, novel compounds represented by general formula (I) and pharmacologically acceptabl e salts thereof have both of the opioid .mu. receptor agonist activity and the  dopamine D2 receptor antagonist activity and are useful as remedies for pain  with regulated side effects.
BACKGROUND: Little is known about the maintenance of amenorrhea among transgender and gender-diverse individuals with uteri who are using long-term testosterone gender-affirming hormone therapy. Emerging data describe breakthrough bleeding among adolescents on long-term testosterone therapy and among adults who are seeking a gender-affirming hysterectomy. More studies are needed to better understand breakthrough bleeding patterns among transgender and gender-diverse individuals with uteri who are using testosterone, including the frequency, timing, and etiology of bleeding and how these patterns may differ between adults and younger populations.
OBJECTIVE: The primary aim of this study was to characterize the incidence and patterns of breakthrough bleeding in a cohort of transgender and gender-diverse individuals who had been on testosterone for longer than 12 months and who had uteri in situ. Secondary aims included identifying the time to first bleed for those who experienced breakthrough bleeding and the risk factors associated with breakthrough bleeding while on testosterone therapy.
STUDY DESIGN: This was an institutional review board-approved, single tertiary center, retrospective chart review of transgender and gender diverse individuals who had been on testosterone for at least 1 year. A primary survival analysis that evaluated the incidence of bleeding was combined with descriptive analyses and an evaluation of the factors associated with bleeding.
RESULTS: Of the 279 patients included in the analysis, the median age of testosterone initiation was 22 years (interquartile range, 19-41), and the median follow-up time was 34 months (range, 12-278). The absolute proportion of individuals who ever experienced breakthrough bleeding on testosterone was 34% (n=96; 95% confidence interval, 29-40). Patients who experienced breakthrough bleeding initiated testosterone at a younger age (20.5 vs 22.0 years; P=.04), had lower mean serum testosterone levels (389.14 vs 512.7 ng/dL; P=.001), were more likely to have a mean testosterone level <320 ng/dL (52% vs 48%; P=.001), and had higher mean estradiol levels (62% vs 49%; P=.003). Survival analyses estimated a breakthrough bleeding incidence rate of 0.09 per year (95% confidence interval, 0.07-1.0). Although 58 people underwent a hysterectomy during the follow-up period, 64% of the cohort who maintained a uterus eventually experienced breakthrough bleeding. The median time to the initial bleeding episode was 22 months (interquartile range, 12-201) after testosterone initiation.
CONCLUSION: These results suggest that a substantial fraction of transgender and gender-diverse individuals who are using testosterone will experience at least 1 episode of breakthrough bleeding even after their initial year of testosterone use. We recommend that clinicians inform all patients that breakthrough bleeding is a common occurrence even after the first year on testosterone therapy.
Informed consent will be obtained from patients presenting with chief complaint of moderate to severe abdominal pain in the emergency department who do not meet any exclusion criteria and who willingly agree to participate by signing the written consent form. Investigators will assess the patient's opioid tolerance by asking if they have use an opioid medication in the last week, prescription opioid use at home, and/or recreational opioid use. Patients in both groups will fill out the pre-treatment questionnaire, which will include demographic questions (age, sex, race, height, weight, etc.), a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction. Post-treatment survey will be given at 30 minutes after administration of medication. The physician will record whether the patient required additional pain medication after the 30 minutes, final emergency department diagnosis, and final emergency department disposition.
The invention relates to an external ointment used for changing medicine for an anal fistula postoperative wound surface and a preparation method thereof. The external ointment is prepared from the following raw materials in parts by weight: 50 parts of balm, 15 parts of yellow wax, 4 parts of vermilion powder, 4 parts of carbonized hair, 1 part of pepper, 2 parts of calomel, 5 parts of aluminum powder and 1 part of amber powder. The preparation method comprises the following steps of: placing the balm into a heated boiler; heating with soft fire; boiling and then adding the carbonized hair; placing the pepper into the boiler after the carbonized hair is turned into yellow, taking out the pepper and the carbonized hair one minute later; then placing the yellow wax into the boiler; stopping heating at the moment; filtering the substances in the boiler into a container after the yellow wax is dissolved; and cooling and then placing the calomel, the aluminum powder, the amber powder and the vermilion powder into the container to be uniformly stirred. The ointment provided by the invention has powerful efficacy of eliminating necrotic tissues, promoting tissue regeneration, astringing sores, detoxificating and relieving pain so as to achieve the purpose of promoting wound surface healing. Compared with the traditional external ointment for changing medicine and cleaning the wound surface, the healing time is shortened, the curative effect is obvious. The preparation method is simple and conveniently utilized.
Participants with moderate-to-severe active CD enrolled in ImproveCareNow (ICN) pediatric Inflammatory bowel disease (IBD) registry will be observed who are being treated with ustekinumab under real world setting and will be divided into 9 cohorts. Cohorts 1-6 for age group \>=2 to \<18 years (pediatric), cohorts 7-9 for young adults within age group \>=18 to \<26 years. Cohort 1: participants with moderate-severe CD and body weight \>=40 kg, cohort 2: participants with moderate-severe CD and body weight \<40 kg, cohort 3: all participants with moderate-severe CD, cohort 4: participants with active disease and body weight \>=40 kg, cohort 5: participants with active disease and body weight \<40 kg, cohort 6: all participants treated with ustekinumab, cohort 7: young adults with moderate-severe CD, cohort 8: young adults with active-disease; and cohort 9: all young adults treated with ustekinumab. Only data available per routine clinical practice will be collected within this study.
<P>PROBLEM TO BE SOLVED: To provide α-D-glucopyanosylglycerols, to provide a method for efficiently producing the α-D-glucopyanosylglycerols, and to provide applications of the α-D-glucopyanosylglycerols.  <P>SOLUTION: The α-D-glucopyanosylglycerols have low Maillard reactivity, heating stability, noncariogenic property, indigestible property and high moisture retention. The α-D-glucopyanosylglycerols are produced by allowing α-glucosidase act on a mixture of glycerol with succharides containing glucose, maltose and the like so as to transfer glucosyl into the glycerol. And, by continuously adding saccharides to a reaction mixture, the concentration of α-D-glucopyanosylglycerols is increased and the glycerols are efficiently produced. The α-D-glucopyanosylglycerols are effectively applied to foods, chemicals and medicines.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
NEW MATERIAL:A compound expressed by formula I[R is residue R of amino acid expressed by the formula R.CH(NH2)COOH; R, together with formula II, may be form formula III]. EXAMPLE:Cyclopentane-3-spiro-6-methyl-piperazine-2,5-dione expressed by formula IV. USE:An immunosuppressive agent. PREPARATION:Cycloleucine expressed by formula V is made to react with a mixture solution of benzyl alcohol, p-toluenesulfonic acid and toluene while being heated and refluxed and then crystallized in an ether to provide a cycloleucine benzyl ester p-toluenesulfonate expressed by formula VI, which is subsequently subjected to a reaction with an amino acid expressed by formula VII in which the amino group is protected with tert-butyloxycarbonyl group in N-methylmorpholine, etc., to afford a compound expressed by formula VIII. The resultant compound expressed by formula VIII is then dissolved in hydrochloric acid-dioxane and the reaction solution is evaporated to dryness. The obtained solid is subsequently dissolved in a solvent and N-methylmorpholine is then added thereto. The reaction mixture is refluxed while being heated.
Clostridium difficile infection (CDI) is considered the most frequent healthcare associated infection in the US, causing almost half a million cases per year with an estimated annual cost of 4.8 billion dollars. Despite the existence of a few treatment options against CDI, yearly attributable deaths are estimated at 29,300 in the US. From April 2014 to April 2016, Froedtert Health reported 899 CDIs. Over half of these events are NAAT (Nucleic Acid Amplification Test)(+)/EIA (Enzyme immunoassay)(-) events. To test for CDI, NAAT followed by EIA is used in a Multistep algorithmic testing in which a sensitive nucleic acid amplification test (NAAT) is followed by a specific toxin A and toxin B enzyme immunoassay (EIA) and are among the most accurate methods for Clostridium difficile infection (CDI) diagnosis. There is currently uncertainty on how to treat these CDI events.

The primary outcome of this randomized double blind controlled intervention trial will be changes in C. difficile (Clostridium difficile) loads between day 1 and day 14 and changes in C. difficile load between day 14 and day 28. Thirty patients with documented C. difficile will be randomized to either 14 days of vancomycin or placebo capsules. Block randomization will be used to assign patients to the treatment or placebo arms. Randomized assignments will be placed in sealed envelopes which will only be handled by the research pharmacist. Study related stool collections will be obtained on days 1, 7, 14, 21, and 28 (+/- 2days) \[Day 1=first day study drug was administered\]. Patients will be followed for 90 days starting on day 1. Patients unable to complete at least 7 days of study treatment will be removed from analysis and replaced.
The SARS-CoV-2 pandemic has highlighted the need to better define in-hospital transmissions, a need that extends to all other common infectious diseases encountered in clinical settings. To evaluate how whole viral genome sequencing can contribute to deciphering nosocomial SARS-CoV-2 transmission 926 SARS-CoV-2 viral genomes from 622 staff members and patients were collected between February 2020 and January 2021 at a university hospital in Munich, Germany, and analysed along with the place of work, duration of hospital stay, and ward transfers. Bioinformatically defined transmission clusters inferred from viral genome sequencing were compared to those inferred from interview-based contact tracing. An additional dataset collected at the same time at another university hospital in the same city was used to account for multiple independent introductions. Clustering analysis of 619 viral genomes generated 19 clusters ranging from 3 to 31 individuals. Sequencing-based transmission clusters showed little overlap with those based on contact tracing data. The viral genomes were significantly more closely related to each other than comparable genomes collected simultaneously at other hospitals in the same city (n = 829), suggesting nosocomial transmission. Longitudinal sampling from individual patients suggested possible cross-infection events during the hospital stay in 19.2% of individuals (14 of 73 individuals). Clustering analysis of SARS-CoV-2 whole genome sequences can reveal cryptic transmission events missed by classical, interview-based contact tracing, helping to decipher in-hospital transmissions. These results, in line with other studies, advocate for viral genome sequencing as a pathogen transmission surveillance tool in hospitals.
Peripheral neuropathy (sensory and motor neuropathy) occurred in patients treated with IXEMPRA in combination with capecitabine and in patients treated with single agent IXEMPRA as shown in Table (see Table 3). 

In Studies 046 and 081, 80% and 87%, respectively, of patients with peripheral neuropathy who received IXEMPRA had improvement or no worsening of their neuropathy following dose reduction. For patients with grade 3 or 4 neuropathy in Studies 046 and 081, 76% and 79%, respectively, had documented improvement to baseline or grade 1, twelve weeks after onset.

A pooled analysis of 1540 cancer patients treated with IXEMPRA indicated that patients with diabetes mellitus or preexisting peripheral neuropathy may be at increased risk of severe neuropathy. Patients with moderate to severe neuropathy (grade 2 or greater) were excluded from studies with IXEMPRA.

Monitor patients for symptoms of neuropathy, such as burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, or neuropathic pain. Withhold, reduce, or discontinue IXEMPRA depending on the severity and persistence of peripheral neuropathy [ see Dosage and Administration (2.3)].
Given that inhibition interacts with visual temporal processing (VTP), the past evidence regarding the influence of VTP on the Chinese character reading of children with dyslexia may not disclose the whole picture without considering inhibition. Thus, the present study is among the first to investigate VTP and cognitive inhibition as well as their relationships to Chinese character reading. We compared the performances of 62 Chinese-speaking children with dyslexia in primary school (n = 62, Mage = 11.36 years) on VTP and inhibition tasks to those in a chronological-age-matched group (CA; n = 62, Mage = 11.57 years) and reading-level-matched group (RL; n = 62, Mage = 8.98 years). The results revealed that children with dyslexia performed worse than both the CA-matched and RL-matched groups in VTP and inhibition after controlling for age, nonverbal intelligence, and attention. Moreover, the relationship between VTP and Chinese character reading was moderated by inhibition in children with dyslexia. VTP is positively related to Chinese character reading, but this relationship is observed only at higher levels of inhibition. Our results suggest that inhibition plays a potential role in VTP and Chinese character reading, especially for those with dyslexia whose proficiency in inhibition is not as intact as that of typically developing children.
Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week 20 and Q12 through Week 32.
Amyotrophic lateral sclerosis (ALS) commonly results in the inability to produce natural speech, making speech-generating devices (SGDs) important. Historically, synthetic voices generated by SGDs were neither unique, nor age- or dialect-appropriate, which depersonalized SGD use. Voices generated by SGDs can now be customized via voice banking and should ideally sound uniquely like the individual's natural speech, be intelligible, and elicit positive reactions from communication partners. This large-scale 2 x 2 mixed between- and within-participants design examined perceptions of 831 adult listeners regarding custom synthetic voices created for two individuals diagnosed with ALS via two synthesis systems in common clinical use (waveform concatenation and statistical parametric synthesis). The study explored relationships among synthesis system, dysarthria severity, synthetic speech intelligibility, naturalness, and preferences, and also provided a preliminary examination of attitudes regarding the custom synthetic voices. Synthetic voices generated via statistical parametric synthesis trained on deep neural networks were more intelligible, natural, and preferred than voices produced via waveform concatenation, and were associated with more positive attitudes. The custom synthetic voice created from moderately dysarthric speech was more intelligible than the voice created from mildly dysarthric speech. Clinical implications and factors that may have contributed to the relative intelligibilities are discussed.